← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #188 OF 1,000 MOST-CITED

Lack of procedures, or not maintained

FDA cited this observation 157 times across 152 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices157
BY FISCAL YEAR
FY20264
FY20259
FY20246
FY202310
FY202218
FY20214
FY202017
FY201924
FY201817
FY201728
FY201620

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.4× the rate of the average FDA-cited firm (10.5% vs 7.7%), across 152 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Document control procedures have not been established.

EPS Bio Technology Corp. · Hsinchu · Devices · 2026-01-15

Document control procedures have not been established.

Banyan USA LLC · Hauppauge, New York · Devices · 2025-11-12

Document control procedures have not been established.

R.G. Enterprises (U.S.A.) Inc. · Madison Heights, Michigan · Devices · 2025-11-05

Document control procedures have not been established.

Merchsource LLC · Irvine, California · Devices · 2025-10-22

Document control procedures have not been established.

Integrity United Inc · Anaheim, California · Devices · 2025-09-25

Document control procedures have not been established.

VirtuSense Technologies, Inc. · Peoria, Illinois · Devices · 2025-09-18

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemMedical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →